SCHEMBL13199142

SCHEMBL13199142

O=C(Cc1cccc(O)c1)NNC(=O)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NLRP3 Q96P20 1/20 0.60
▸ PLAU P00749 1/20 0.53
▸ ELANE P08246 1/20 0.53
▸ TRPV1 Q8NER1 5/20 0.51
▸ TLR7 Q9NYK1 3/20 0.51
▸ MRGPRX4 Q96LA9 2/20 0.49
▸ MAPK14 Q16539 1/20 0.49
▸ HDAC3 O15379 1/20 0.48
▸ HDAC1 Q13547 1/20 0.48
▸ HDAC2 Q92769 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ HTR2C P28335 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13199228 0.89 NLRP3 (0.53) NLRP3PLAUELANEMRGPRX4MAPK14
SCHEMBL13199209 0.84 PLAU (0.76) NLRP3PLAUELANEALDH1A1NPC1
SCHEMBL13199110 0.83 KDM4E (0.55) PLAUELANEALDH1A1KDM4EMEN1
SCHEMBL13199150 0.82 PLAU (0.58) PLAUELANEALDH1A1NPC1RAB9A
SCHEMBL13199195 0.82 ALDH1A1 (0.58) PLAUELANEALDH1A1NPC1RAB9A
SCHEMBL13199109 0.81 PLAU (0.61) PLAUELANEMRGPRX4HDAC3HDAC1
SCHEMBL13199217 0.81 ALDH1A1 (0.53) NLRP3PLAUELANEALDH1A1NPC1
SCHEMBL13199218 0.81 NR1H4 (0.52) NLRP3PLAUELANETRPV1ALDH1A1
SCHEMBL13199231 0.80 TDP1 (0.62) PLAUELANEALDH1A1KDM4EMEN1
SCHEMBL13199222 0.80 ALDH1A1 (0.75) NLRP3PLAUELANEALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767716-B2 Acyl hydrazines as kinase inhibitors, in particular for SGK MERCK PATENT GMBH (DE) 2010-08-03 — — US disclosed
US-7767716-B2 Acyl hydrazines as kinase inhibitors, in particular for SGK MERCK PATENT GMBH (DE) 2010-08-03 — — US disclosed
EP-1866280-B1 ACYL HYDRAZIDES AS KINASE INHIBITORS, IN PARTICULAR FOR SGK MERCK PATENT GMBH (DE) 2008-08-13 — — EP disclosed
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk MERCK PATENT GMBH (DE) 2008-07-10 — — US disclosed
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk MERCK PATENT GMBH (DE) 2008-07-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk SGK1, AGK, SGK2 NLRP3 3060/4885PLAU 2508/4885ELANE 3387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback